Global B-cell Non Hodgkin Lymphoma Drugs Market 2018-2022: Key Vendors are Biogen, F. Hoffmann-La Roche, Merck, Novartis & Spectrum Pharmaceuticals

DUBLIN, Sept 11, 2018 /PRNewswire/ --

The "Global B-cell Non Hodgkin Lymphoma Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The Global B-Cell Non-Hodgkin Lymphoma Drugs Market to grow at a CAGR of 7.52% during the period 2018-2022.

Global B-cell non-Hodgkin Lymphoma Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the retail sales of B-cell non-Hodgkin lymphoma drugs across the globe.

According to the report, one driver influencing this market is the growing government initiatives. Increasing government initiatives such as Cancer Breakthrough 2020 are driving the growth of the market across the globe. One trend affecting this market is the strong pipeline. The count of pipeline in the B-cell non-Hodgkin lymphoma drugs market is increasing rapidly which is expected to boost the growth of the market.

Further, the report states that one challenge affecting this market is the high cost of treatment. The high cost of treatment is impeding the growth of the global B-cell non-Hodgkin lymphoma drugs market.

Key vendors

• Biogen
• F. Hoffmann-La Roche
• Merck
• Novartis
• Spectrum Pharmaceuticals

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY CATEGORY

• Comparison by category
• Small molecules
  
• Biologicals
  
• Market opportunity by category

PART 09: REGIONAL LANDSCAPE

• Geographical segmentation
• Regional comparison
• Market opportunity

PART 10: CUSTOMER LANDSCAPE

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

• Strong pipeline
• Strategic alliances
• Advanced technologies

PART 14: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 15: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
  

For more information about this report visit

https://www.researchandmarkets.com/research/clvpnr/global_bcell_non?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content to download multimedia:http://www.prnewswire.com/news-releases/global-b-cell-non-hodgkin-lymphoma-drugs-market-2018-2022-key-vendors-are-biogen-f-hoffmann-la-roche-merck-novartis--spectrum-pharmaceuticals-300710431.html

SOURCE Research and Markets